Damora Therapeutics (DMRA) Shares Outstanding (Weighted Average) (2019 - 2026)

Damora Therapeutics has reported Shares Outstanding (Weighted Average) for 8 years, with the latest figure at $34.3 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 2494.47% year-over-year to $34.3 million; the trailing twelve-month figure through Mar 2026 stood at $34.3 million (up 2494.47% YoY), and the FY2025 full-year result was $1.4 million, up 17.79% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $34.3 million, up from $1.4 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $34.3 million in Q1 2026, with the low at $1.1 million in Q3 2023.
• Historically, Shares Outstanding (Weighted Average) has averaged $11.7 million across 5 years, with a median of $1.3 million in 2025.
• Annual changes were most pronounced in 2024 — Shares Outstanding (Weighted Average) slumped 95.89% — and 2026, when it surged 2494.47%.
• Damora Therapeutics' Shares Outstanding (Weighted Average) stood at $25.4 million in 2022, then sank by 95.82% to $1.1 million in 2023, then advanced by 8.87% to $1.2 million in 2024, then rose by 17.79% to $1.4 million in 2025, then soared by 2416.44% to $34.3 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $34.3 million (Q1 2026), $1.4 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.